secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001819790-23-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q1 net loss $23.4M; cash $201.2M; TP-03 PDUFA Aug 25
-----------------------------------------------------------

- Net loss of $23.4M vs $20.2M in Q1 2022; revenue $2.5M from LianBio partnership.
- Cash and marketable securities $201.2M as of March 31, 2023.
- TP-03 (Demodex blepharitis) PDUFA date August 25, 2023; 93% of eye doctors would prescribe if approved.
- Phase 2a trials ongoing for TP-04 (rosacea), TP-05 (Lyme prevention), and TP-03 (MGD).
- Appointed Jeff Farrow as CFO and Chief Strategy Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/0001819790-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/tars-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001819790-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer